

HEART FAILURE ASSOCIATION OF INDIA

IN ASSOCIATION WITH



HEART FAILURE ASSOCIATION OF THE ESC



24th & 25th Feb 2018

WELCOME

Warm welcome to the Heart Failure Association of India 2018 meeting which will be held jointly with the Heart Failure Association of Europe at the exquisite venue of J W Marriott, Mumbai from February 24-25. As you will notice in the program brief, we have incorporated a comprehensive review on heart failure – from bedside to bench, so that the clinical science of Heart Failure is discussed in details. The scientific meeting will have accreditation from the Medical council.

Amongst the galaxy of faculty, we will have the pleasure to interact with Professor Stefan Anker, Professor Inder Anand, Professor Wolfram Doehner and Professor Jeanette Schulz-Menger.

Heart Failure has evolved into a science which requires involvement of Nursing care, Clinical expertise and Physicians outpatient care, Hospital team approach compromising of Cardiologist, Critical Care Specialist, Nephrologist, Electrophysiologist and Cardiac Surgeons. This concept is getting stronger by the day in India and has led to effective patient - oriented cardiac rehabilitation.

We believe that the scientific meeting targeted at Heart Failure will have to merge the wisdom of faculties from India, Europe and the Delegates and we urge you to keep it interactive.

Warm Regards and Thanks



Dr. Uday M. Jadhav Organizing Chairman



Dr. V. K. ChopraPresident

Heart Failure Association of India





HEART FAILURE ASSOCIATION OF INDIA

Board of Governers

Dr Naresh Trehan

Dr. Inder S Anand

Dr. D B Pahlajani

Dr. B Somaraju

Dr. G Vijayaraghavan

President

Dr. V K Chopra

Vice President

Dr. B K S Sastry

Secretary

Dr. Sanjay Mittal

Joint Secretary

Dr. Uday M Jadhav

Treasurer

Dr. Hari Krishnan

Executive Council

Dr. Balakrishnan

Dr. Abraham Ooman

Dr. P P Mohanan

Dr. Bagirath Raghuraman





HEART FAILURE ASSOCIATION OF INDIA

TEAM HFAI 2018

PRESIDENT

DR. V K CHOPRA

PATRONS

DR. NARESH TREHAN

DR. D B PAHALAJANI

DR. INDER ANAND

ORGANIZING CHAIRMAN

DR. UDAY M JADHAV

SCIENTIFIC COMMITTEE

DR. STEFAN ANKER

DR. V K CHOPRA

DR. UDAY M JADHAV

DR. GRKANE

DR. PRAFULLA KERKAR

DR. BRIAN PINTO

ORGANISING COMMITTEE

DR. AJAY CHAURASIA

DR. AJAY MAHAJAN

DR. MILIND PHADKE

DR. ANAND RAO

DR. BHAVESH VAJIFDAR

DR. SOMNATH MALLAKMIR

DR. AMIT SARAF

HEART FAILURE 2018 – BEDSIDE TO BENCH

HALLA&B

SHORT LECTURES

BEDSIDE CLINIC IN HEART FAILURE

CVP assessment as indicator of fluid accumulation

Bendopnea - Novel and simple symptom in Heart Failure

LABORATORY TESTS IN HEART FAILURE

Inflammatory Markers in Acute Heart Failure

Troponins in Acute Heart Failure

ST2 in Acute Heart Failure

Renal Function Parameters in Acute Heart Failure

ECHOCARDIOGRAPHY IN HEART FAILURE

LV Ejection Fraction – What is normal

Tissue Doppler and Strain Imaging - Simplifying the art

Left atrial size, volume and function

Mistakes in Echo in Heart Failure

RV - THE OTHER FACE OF HEART FAILURE

Echo assessment of RV function

Echo assessment of TR

CMR of Right Ventricle in Heart Failure

CARDIAC MRI FOR PRACTICING CARDIOLOGIST



DIURETIC THERAPY IN HF- ONE SIZE DOES NOT FIT ALL

Fine tuning Diuretic therapy in Acute and Chronic HF

What is Diuretic Resistance

When to use Ultrafiltration

How to keep patients with HF out of hospital

HEART FAILURE- HYPERTENSION TO HEART FAILURE

Preventing the Transition

Which Blood Pressure lowering drugs will make the difference

HEART FAILURE- ATRIAL FIBRILLATION AND HEART FAILURE

Atrial Fibrillation - Targeting heart failure prevention

NOAC's in Atrial Fibrillation and Heart Failure- Current Update

SHORT LECTURES

DIABETES DRUGS AND HEART FAILURE - OLD AND THE NEW

Metformin - Protection from Heart Failure

Gliptins – Heart Failure Concerns: Myths and Realities

Liraglutide - Cardiovascular Protection: Emerging Data

SGLT2 INHIBITION- NEED TO CLOSE THE GAPS IN HEART FAILURE

Empagliflozin

Canagliflozin

Dapagliflozin

SGLT2 Inhibitors- Benefits of the Class Effect and what the future holds



SHORT LECTURES

PERIPARTUM CARDIOMYOPATHY

Top Ten Messages from the ESC Guidelines

Optimizing Clinical Management in Peripartum Cardiomyopathy

SHORT LECTURES

CARDIOGENIC SHOCK - UPDATE 2018

Pathophysiology for Clinicians

Monitoring the patient

Which Catecholamines

Mechanical Assist Device

SHORT LECTURES

CARDIO-RENAL SYNDROME

Worsening renal failure in HF

Treatment of renal dysfunction in HF

GUEST LECTURES

HEART FAILURE IN DIABETES MELLITUS-MANAGEMENT PROTOCOLS

VACCINATION IN HEART FAILURE AND EFFECTS ON OUTCOME

BAROREFLEX ACTIVATION THERAPY IN HEART FAILURE AND RESISTANT HYPERTENSION

METABOLIC MODULATION IN HEART FAILURE

IRON DEFICIENCY IN HEART FAILURE - FACTS, MYTHS AND SOLUTION

HEART FAILURE WITH PRESERVED EJECTION FRACTION - NEW THOUGHTS ON DRUGS &

DEVICES

CRYPTOGENIC STROKE AND EMBOLIC STROKE OF UNDETERMINED SOURCE (ESUS)

LVAD IMPLANTATION- HOW WILL WE POSITION IT IN INDIA





DEBATES

DRUGS IN HEART FAILURE - HORSES FOR THE COURSE

Beta Blockers in AF and HF – Time to Move On

Beta Blockers in AF and HF- Don't Bury them as yet

Chairperson: My Conclusions- Finding the sweet spot

ACE Inhibitors - Phase them out

ACE Inhibitors – Benefits Robust

Chairperson: My Conclusions-Finding the sweet spot

MRA's - Potential Limitations for dose benefits

MRA's – Use them early; very early

Chairperson: My Conclusions- Finding the sweet spot

DRUGS IN HEART FAILURE - HAVING A RELOOK

Ivabradine – Lowering HR with Beta blockers optimization is enough

Ivabradine – Beta Blockers or No beta blockers, Ivabradine is must

Chairperson: My Conclusions- Finding the sweet spot

Tolvaptan - No more studies please, no benefits

Tolvaptan – Only option for low sodium, identify the non-rsponders

Chairperson: My Conclusions- Finding the sweet spot

Hydrallazine- Isosorbide Nitrate – No substantial benefit

Hydrallazine- Isosorbide Nitrate – Option for HF with Renal Dysfunction

Chairperson: My Conclusions- Finding the sweet spot

Amiodarone – No benefits, potential harm

Amiodarone – What else to treat arrhythmias

Chairperson: My Conclusions- Finding the sweet spot

Digoxin – Change old thoughts, not even a reserve drug

Digoxin- Old man has still something to offer

Chairperson: My Conclusions- Finding the sweet spot

PANEL DISCUSSION

SACUBITRIL-VALSARTAN IN HEART FAILURE: GOING BEYOND THE TRIALS

Sacubitril Valsartan in HF with reduced GFR

Sacubitril Valsartan in HF with SBP less than 100mm Hg

Sacubitril Valsartan in Post MI with HF

Sacubitril Valsartan in ACEI naïve patients with HF

Sacubitril Valsartan in elderly with HF

Sacubitril Valsartan in HF NYHA Class III and IV

PANEL DISCUSSION

HEART FAILURE WITH REDUCED MID-RANGE EF (HFMREF) & GUIDELINE BASED THERAPY

ENABLING AND OPTIMISIZING RAAS INHIBITON THERAPY IN CARDIORENAL PATIENT -

THROUGH HYPERKALEMIA MANAGEMENT

STATINS IN HEART FAILURE - WILL IT HAVE A IMPACT ON THE OUTCOMES

DEVICE THERAPY FOR HEART FAILURE - RECENT DEVELOPMENTS

PANEL DISCUSSION

PULMONARY EMBOLISM - 2018 UPDATE

Evidence Based Therapy

Low Risk PE

Intermediate Risk PE

High Risk PE

PERSPECTIVES

Multivessel PTCA in CAD with LVEF < 30% - My Perspectives

CABG in CAD with LVEF < 30% - My Perspectives

SHORT LECTURES





SHORT LECTURES

RIGHT HEART FAILURE IN PULMONARY HYPERTENSION

Therapeutic Options for Primary Pulmonary Hypertension

Pulmonary Thrombo Endarterectomy for CTEPH

SHORT LECTURES

HEART TRANSPLANT PROGRAM

Protocols and Training for Initial Setup

Experience with the early transplant patients- Overcoming the difficulties

Experience with the established transplant patients – Fine tuning for the future

NURSING ASPECTS IN HEART FAILURE

HFAI AND EUROPEAN SOCIETY OF HEART FAILURE- JOINT SESSION





SECRETERIAT AND COMMUNICATION DETAILS

Dr. Uday M. Jadhav

C 5/ 12 GROUND FLOOR,
CENTRAL BUSINESS DISTRICT (CBD),

NEW MUMBAI:- 400 614.

Email: hfaimumbai2018@gmail.com

Contact Cell: 9821023745 / 9833093745

